WS

West Pharmaceutical Services, Inc. stock research

Sep 30, 2024

FY2024 Q3

West Pharmaceutical Services (WST) Gross Margin — Quarter Ended Sep 30, 2024

Revenue was essentially unchanged compared to the same quarter last year, while gross profit and gross margin were lower. Sequentially, revenue increased and gross margin improved, as cost of revenue rose less than revenue.

Gross margin takeaway

Quarter ended Sep 30, 2024 · FY2024 Q3

Revenue was essentially unchanged compared to the same quarter last year, while gross profit and gross margin were lower. Sequentially, revenue increased and gross margin improved, as cost of revenue rose less than revenue.

  • The sequential improvement in gross margin was the most notable change, driven by a smaller increase in cost of revenue relative to the increase in revenue.
  • Compared to the prior quarter, gross margin improved. Compared to the same quarter last year, gross margin weakened.

Gross margin snapshot

The selected quarter's reported revenue, gross profit, direct costs, and margin comparisons.

Gross margin

35.4%

Gross profit

$264.7M

Revenue

$746.9M

Cost of revenue

$482.2M

Quarter-over-quarter change

+2.7 pts

Year-over-year change

-3.1 pts

Quarterly gross margin trend

A four-quarter view of the revenue and direct-cost bridge behind gross margin.

PeriodRevenueGross profitCost of revenueGross margin
Dec 31, 2023$732.0M$278.2M$453.8M38.0%
Mar 31, 2024$695.4M$230.2M$465.2M33.1%
Jun 30, 2024$702.1M$230.0M$472.1M32.8%
Sep 30, 2024$746.9M$264.7M$482.2M35.4%

Quarterly comparisons

Compare the selected margin with the preceding quarter and the same fiscal quarter one year earlier.

Previous-quarter change

Jun 30, 2024

+2.7 pts

Year-over-year change

Sep 30, 2023

-3.1 pts

What the margin says

Filing-constrained interpretation of margin direction, comparisons, and what to monitor next.

The sequential improvement in gross margin was the most notable change, driven by a smaller increase in cost of revenue relative to the increase in revenue.

Compared to the prior quarter, gross margin improved. Compared to the same quarter last year, gross margin weakened.

Monitor capital expenditure trends as they relate to additional manufacturing capacity and potential future cost implications.